TOXICITY GRADING CRITERIA OF THE JAPAN CLINICAL ONCOLOGY GROUP

[1] (1979)

[2] Oken M.M., Creech R.H., Tormey D.C., Horton J., Toxicity and response criteria of the Eastern Cooperative Oncology Group, Am J Clin Oncol, 5, pp. 649-655, (1982)

[3] Nippon Gan Chiryo Gakkai Shi, 21, pp. 929-942, (1986)

[4] Criteria for the evaluation of the clinical effects of solid cancer chemotherapy, Nippon Gan Chiryo Gakkai Shi, 28, pp. 101-130, (1993)

[5] Manual of Oncologic Therapeutics 1991/1992, pp. 445-448, (1991)

[6] Bearman S.I., Appelbaum F.R., Buckner C.D., Petersen F.B., Fisher L.D., Clift R.A., Thomas E.D., Regimen-related toxicity in patients undergoing bone marrow transplantation, J Clin Oncol, 6, pp. 1562-1568, (1988)

[7] Mulder P.O., Sleijfer D.T., Willemse P.H., De Vries E.G., Uges D.R., Mulder N.H., High-dose cyclophosphamide or melphalan with escalating doses of mitoxantrone and autologous bone marrow transplantation for refractory solid tumors, Cancer Res, 49, pp. 4654-4658, (1989)

[8] Beelen D.W., Quabeck K., Graeven U., Sayer H.G., Mahmoud H.K., Schaefer U.W., Acute toxicity and first clinical results of intensive postinduction therapy using a modified busulfan and cyclophosphamide regimen with autologous bone marrow rescue in first remission of acute myeloid leukemia, Blood, 74, pp. 1507-1516, (1989)

[9] Moormeier J.A., Wiluams S.F., Kaminer Ls1 Garner M., Bitran J.D., High-dose tri-alkylator chemotherapy with autologous stem cell rescue in patients with refractory malignancies, J Natl Cancer Inst, 82, pp. 29-34, (1990)

[10] Ellis E.D., Williams S.F., Moormeier J.A., Kaminer L.S., Bitran J.D., A phase I-II study of high-dose cyclophosphamide, thiotepa and escalating doses of mitoxantrone with autologous stem cell rescue in patients with refractory malignancies, Bone Marrow Transplant, 6, pp. 439-442, (1990)

[1] (1979)

[2] Oken M.M., Creech R.H., Tormey D.C., Horton J., Toxicity and response criteria of the Eastern Cooperative Oncology Group, Am J Clin Oncol, 5, pp. 649-655, (1982)

[3] Nippon Gan Chiryo Gakkai Shi, 21, pp. 929-942, (1986)

[4] Criteria for the evaluation of the clinical effects of solid cancer chemotherapy, Nippon Gan Chiryo Gakkai Shi, 28, pp. 101-130, (1993)

[5] Manual of Oncologic Therapeutics 1991/1992, pp. 445-448, (1991)

[6] Bearman S.I., Appelbaum F.R., Buckner C.D., Petersen F.B., Fisher L.D., Clift R.A., Thomas E.D., Regimen-related toxicity in patients undergoing bone marrow transplantation, J Clin Oncol, 6, pp. 1562-1568, (1988)

[7] Mulder P.O., Sleijfer D.T., Willemse P.H., De Vries E.G., Uges D.R., Mulder N.H., High-dose cyclophosphamide or melphalan with escalating doses of mitoxantrone and autologous bone marrow transplantation for refractory solid tumors, Cancer Res, 49, pp. 4654-4658, (1989)

[8] Beelen D.W., Quabeck K., Graeven U., Sayer H.G., Mahmoud H.K., Schaefer U.W., Acute toxicity and first clinical results of intensive postinduction therapy using a modified busulfan and cyclophosphamide regimen with autologous bone marrow rescue in first remission of acute myeloid leukemia, Blood, 74, pp. 1507-1516, (1989)

[9] Moormeier J.A., Wiluams S.F., Kaminer Ls1 Garner M., Bitran J.D., High-dose tri-alkylator chemotherapy with autologous stem cell rescue in patients with refractory malignancies, J Natl Cancer Inst, 82, pp. 29-34, (1990)

[10] Ellis E.D., Williams S.F., Moormeier J.A., Kaminer L.S., Bitran J.D., A phase I-II study of high-dose cyclophosphamide, thiotepa and escalating doses of mitoxantrone with autologous stem cell rescue in patients with refractory malignancies, Bone Marrow Transplant, 6, pp. 439-442, (1990)